Present

BIOTECH WEBINAR

11AM, MONDAY, SEPTEMBER 27th

-
Days
-
Hours
-
Minutes
-
Seconds
REPLAY AVILABLE

Explore latest trends at the forefront of medical innovation across biotech and pharmaceuticals.

With on-the-ground insights from Industry Leaders

Michael Holder
CFO, Avita Medical
(ASX:AVH)

Dr Michelle Miller
CEO & MD, Biotron
(ASX:BIT)

Dr Paul Gavin
CEO, Avecho Biotech
(ASX:AVE)

Gary J Phillips
CEO, Pharmaxis
(ASX:PXS)

Conor Daley
PEAK Asset
Management

FEATURED COMPANIES

EXPLORING THE BIOTECH LANDSCAPE

COVID-19 has put an increasing spotlight on biotechs. In this webinar we will aim to understand the risks and opportunities within the market landscape.

BIOTECH AS AN INVESTMENT

Understanding the business and investment case for biotech, as well as a deep dive into the featured companies.

WHAT'S INCLUDED?

INSIGHTS FROM INDUSTRY LEADERS

LATEST INVESTMENT TRENDS

RISKS AND OPPORTUNITIES

FEATURED COMPANIES

Avecho developed a world first enhanced Vitamin E drug delivery platform TPM®, to improve the solubility and absorption of drugs. TPM® has the potential to increase effectiveness and reduce the side effects of drugs currently on the market. The company is also developing a CBD soft-gel capsule for insomnia.

Biotron is developing new drugs to much more effectively treat virus conditions such as SARS, HIV-1, influenza and dengue fever - ail very serious diseases. The company's lead drug shows potential as part of a combination therapy to eradicate HIV-1.

AVITA Medical is a regenerative medicine company with an innovative skin restoration technology platform RECELL ® positioned to address unmet needs in burns, chronic wounds, and aesthetics indications. ln the U.S., RECELL is indicated for the treatment of acute thermal burn wounds by an appropriately-licensed healthcare professional at the patient's point of care. ln addition to its burns business, AVITA Medical is currently conducting U.S. FDA pivotai trials in the usage of RECELL ® in soft tissue reconstruction and vitiligo, as well as pre-clinical research in the usage of RECELL ® for skin rejuvenation and the treatment of Epidermolysis Bullosa.

Pharmaxis' lead drug candidate is in clinical trials targeting the bone cancer myelofibrosis where it has disease modifying potential. Pharmaxis also has two FDA-approved products on market - Bronchitol® for respiratory disease cystic fibrosis and Aridol® for asthma.

DONT MISS THIS WEBINAR

WATCH THE REPLAY